A new screening platform systematically finds drugs that tag disease proteins for disposal — including targets that conventional inhibitors can’t touch.
The Korean biotech will tap Eli Lilly’s labs, scientists and infrastructure to speed its RNA-based gene therapies — an incubator arrangement, not an acquisition.
In supercentenarians, a rare hybrid “killer-helper” T cell made up nearly a fifth of all T cells — hinting the immune system keeps adapting even in extreme old age.
Analyzing thousands of people, researchers found that drugs from antibiotics to antidepressants left fingerprints in the gut — some detectable years after the last dose.
The KRAS G12C inhibitor earned the designation for previously treated advanced pancreatic cancer, one of oncology’s hardest targets, based on early-phase trial data.
As GLP-1 drugs go from niche to blockbuster, the industry is scrambling for the specialized manufacturing skills needed to keep up with demand.
Whole-genome sequencing of the parasite behind the deadliest malaria uncovered new mutations linked to reduced susceptibility to frontline artemisinin-based therapy.
A new MassBio snapshot shows venture money and IPOs surging even as the industry sheds jobs — a split between thriving young companies and downsizing giants.
Older adults who got the Shingrix vaccine had notably lower dementia rates over four years, adding to a growing body of intriguing but not-yet-conclusive evidence.
The manufacturer will produce an AAV9 gene therapy for GM2 gangliosidosis — a group of fatal inherited disorders — developed with Queen’s University ahead of planned clinical trials.
An observational analysis of more than 31,000 patients tied one widely used class of blood-pressure pills to a 33% higher risk of serious kidney events — though researchers stress it cannot prove cause.
In lab-infected human immune cells, dexamethasone dialed down damaging inflammation from a stubborn lung infection while still letting the cells fight the bacteria.